| payload |
{"created_at":"2026-04-10T03:04:31.796 {"created_at":"2026-04-10T03:04:31.796915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:62871b9bef0e94e6","evidence_event_ids":["evt_886d63369bf8"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001794362-26-000002.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001794362-26-000002.txt","company":"Vistagen Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001794362-26-000002.txt","article_chars":2080,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_0febf492ea58df23","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001794362-26-000002.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:15:01.876736+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001794362-26-000002.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001794362-26-000002.txt","source_event_id":"evt_886d63369bf8","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"6ba4b06d81d68e2d","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-07","2026-04-09","2026-04-10","2036-04-04","2011-06-10","2007-09-06"],"entities":[{"asset_class":"equity","name":"Vistagen Therapeutics, Inc.","relevance":"high","symbol":"VTGN","type":"issuer"},{"asset_class":"person","name":"Nick B. Tressler","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity_compensation","name":"2019 Omnibus Equity Incentive Plan (as amended)","relevance":"medium","symbol":"","type":"equity_plan"}],"event_type":"other","information_gaps":["The signal text does not include the prior known state (e.g., whether this was previously disclosed or newly granted), so the 'delta vs prior' cannot be determined from the provided content alone.","The filing text excerpt does not explicitly state whether this is the only transaction in the Form 4 beyond the single listed option grant line.","No purchase/sale price or consideration is shown in the provided excerpt (only option grant and vesting details)."],"key_facts":["SEC accession number: 0001794362-26-000002.","Form type: 4; issuer: Vistagen Therapeutics, Inc.; filed as of date: 2026-04-09; conformed period of report: 2026-04-07.","Reporting owner: Nick B. Tressler, identified as Chief Financial Officer.","Transaction type indicated: Incentive Stock Option (right to buy).","Number of options: 75,000.","Grant date shown: 2026-04-07.","Expiration/option term shown: 2036-04-04 (as displayed in the filing text).","Vesting: 25% of the options vest on the six-month anniversary of April 7, 2026; remaining vesting occurs in 25% installments every six months thereafter until fully vested on the two-year anniversary of the grant date.","Options are stated to be granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended."],"numeric_claims":[{"label":"Options granted","value":"75000"},{"label":"Grant date","value":"2026-04-07"},{"label":"Vesting start (6-month anniversary of grant date)","value":"2026-10-07"},{"label":"Full vesting (2-year anniversary of grant date)","value":"2028-04-07"}],"primary_claim":"Form 4 (filed 2026-04-09) discloses that CFO Nick B. Tressler received an Incentive Stock Option grant of 75,000 options with vesting starting 6 months after April 7, 2026 and completing at the 2-year anniversary.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Vistagen Therapeutics, Inc. (VTGN) filed a Form 4 on 2026-04-09 covering a stock option grant to CFO Nick B. Tressler dated 2026-04-07.","topics":["SEC Form 4","insider transaction","incentive stock options","vesting schedule","equity incentive plan"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Vistagen Therapeutics, Inc. \u00b7 Filed 20260409","ticker":"VTGN","tickers":["VTGN"],"title":"VTGN filed 4","url":"https://www.sec.gov/Archives/edgar/data/1411685/0001794362-26-000002.txt"}}... |